Tuesday
06.02.2026
11:48 AM
Login form
Search
Calendar
«  June 2026  »
Su Mo Tu We Th Fr Sa
 123456
78910111213
14151617181920
21222324252627
282930
Entries archive

My site

Main » 2026 » June » 02

TAIPEI, Taiwan - Monday, 01. June 2026 AETOSWire


(BUSINESS WIRE) -- Following the introduction of its "Future Landing" vision, GIGABYTE Technology, a global leader in high-performance computing and AI infrastructure, brings that vision to life at COMPUTEX 2026 through a comprehensive showcase of systems, software, and real-world deployments that demonstrate how AI infrastructure is built, deployed, and operated at scale. From rack-scale AI factories and modular data centers to Physical AI workflows, clinical AI applications, and on-prem AI agents, GIGABYTE demonstrates how AI infrastructure moves beyond planning and into production.

Rack-Scale Infrastructure, Validated for AI Factories

At the foundation of “Future Landing” is GIGABYTE’s expanding portfolio of rack-scale AI infrastructure designed for next-generation AI factories.

Among the latest highlights is the NVIDIA Vera Rubin NVL72, showcased as part of GIGABYTE’s broader rack-scale portfolio. ... Read more »

Views: 9 | Added by: africa-live | Date: Today | Comments (0)

SAN CARLOS, Calif. - Monday, 01. June 2026 AETOSWire Print Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across solid tumor pipeline (BUSINESS WIRE) -- BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. Data from three differentiated BeOne pipeline assets will be presented, including: CDK4 inhibitor (BGB-43395) (poster presentation): First disclosure of anti-tumor activity in first-line (1L) HR+/HER2- metastatic breast cancer. B7-H4 ADC (BG‑C9 ... Read more »

Views: 11 | Added by: africanewsline | Date: Today | Comments (0)


(BUSINESS WIRE)--Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives.

... Read more »

Views: 14 | Added by: africa-live | Date: Today | Comments (0)